

Sung-Hee Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7586096/publications.pdf>

Version: 2024-02-01

8
papers

378
citations

1937685

4
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

832
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib for Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495.	1.6	233
2	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. <i>European Journal of Cancer</i> , 2016, 52, 1-9.	2.8	115
3	Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 1379.	4.4	12
4	Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S217-S224.	1.7	6
5	TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. <i>Current Issues in Molecular Biology</i> , 2021, 43, 917-931.	2.4	5
6	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. <i>Yonsei Medical Journal</i> , 2021, 62, 671.	2.2	4
7	Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 957-969.	1.7	3
8	microRNA-22 and TET-2 Mutation in Myelodysplastic Syndrome Patients Treated with Hypomethylating Agents. <i>Blood</i> , 2018, 132, 5127-5127.	1.4	0